Sweden Inga-Lill Andersson

Partner - Awapatent AB

Inga-Lill Andersson is a senior European patent attorney specialising in the fields of chemistry and biotechnology, with a particular focus on protein chemistry, pharmaceutical chemistry, biochemistry and implant technology.

In her daily work, Ms Andersson engages in all types of patent-related issue encompassing infringement and validity, such as patentability evaluations, drafting and prosecution of patent applications, due diligence investigations and freedom-to-operate analyses.

Ms Andersson has comprehensive experience of oppositions and appeals before the European Patent Office (EPO). She also completed an internship at a Technical Board of Appeal at the EPO’s headquarters in Munich. Further, Ms Andersson has participated extensively in a number of national litigation procedures, at both first and second instance. Ms Andersson also has a Centre for International Intellectual Property Studies diploma in European patent litigation from Strasbourg University.

Ms Andersson has lectured at numerous continuing legal education seminars in the United States, and is a frequent author of articles on European patent law and practice.

Ms Andersson led the work of Awapatent AB’s specialist group for life science-based inventions for seven years and is now team manager of the chemistry team in Stockholm. In 2013 she was one of four experienced consultants responsible for opening a new Awapatent branch office in Uppsala, a renowned region for biotechnological research.

Before joining Awapatent in 2000, Ms Andersson worked as an analytical chemist at AstraZeneca R&D.

Professional associations

  • EPI

Firm details

Awapatent AB
Jakobsbergsgatan 36
PO Box 45086
Stockholm 104 30
Sweden

Contact details

E: inga-lill.andersson@awapatent.com
T: +46 8 440 95 00
F: +46 8 440 95 50
W: www.awapatent.com

Related articles

Life sciences patent strategies in Europe
IP in the life sciences industries 2009

The European market can be a daunting one, due to the lack of a unified patent system. However, life sciences companies can employ a number of tactics in order to arrive at a successful IP strategy for patent protection

Close

Register for more free content

  • Read more IAM blogs and articles
  • Receive the editor's weekly review by email
Register now  
Issue 82